
Opinion|Videos|January 31, 2024
Key Considerations in Managing Hypertension Risk with BTKis in CLL
Amber Koehler, PA-C, provides expert perspective on addressing hypertension risk in CLL patients undergoing treatment with BTK inhibitors.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
2
ASCO 2026: Practice-Guiding Updates in Bladder and Kidney Cancer
3
VS-7375 Exhibits Activity in KRAS G12D–Mutated Solid Tumors
4
FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer
5





















































































